HEB, Hemispherx Biopharma (AMEX)NEW Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Marty who wrote (497)	10/24/1998 1:11:00 PM
From: Cavalry	of 857

the downside factor is key point, what i found in my ampligen research was that in canadien tests, the length of each treatment varied between doctors. the length of each treatment ideally was 1/2 hour. read one patient who had negative reactions to ampligen reived his treatments in one hour durations not proper 1/2 hour, seems by slowing down speed of iv causes soreness and discomfort. olsten administering tests will turn out to be big plus for heb, i didnt realize olsten agreed to lay out money to purchase the supply of ampligen they will be administering, lot of choice info re alliances heb has in sec filing from 8/17, most of those alliances entail a way to produce massive amounts of ampligen at far lower costs to meet expected future world wide demand for ampligen. cav

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next